Microbiome Market Definition

The microbiome market consists of sales of microbiome and related services used as immunotherapeutic agents in the pharmaceutical industry. Microbiomes are used as immunotherapy for a wide variety of conditions, including infectious diseases, endocrine and metabolic disorders, inflammatory conditions, cancers, irritable bowel syndrome, neurological disorders, hematological disorders and cardiovascular diseases. The microbiome consists of the genetic material within a microbiota, which is the collection of microorganisms, such as bacteria, archaea, fungi, and viruses living in humans, animals, plants, soil and other habitats. For example, the gut microbiome consists of collective genome of microbes inhabiting the gut. Microbiomes are also known as the metagenome of the microbiota.

Bioinformatics, which is connected to genetics and genomics, uses computer technology to gather, store, analyze, and share biological information and data such as DNA and amino acid sequences or annotations about those sequences.  The main product and service types of bioinformatics are knowledge management tools, data analysis platforms, and services. Knowledge management tools are technologies used by organizations to share information both internally and externally. The various applications include metabolomics, molecular phylogenetics, transcriptomics, proteomics, chemoinformatics, genomics, and others that are used by pharmaceutics, animal studies, agriculture, forensic science, and other end users. The bioinformatics market research report is one of a series of new reports from The Business Research Company that provides bioinformatics market statistics, including bioinformatics industry global market size, regional shares, competitors with a bioinformatics market share, detailed bioinformatics market segments, market trends and opportunities, and any further data you may need to thrive in the bioinformatics industry. This bioinformatics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global bioinformatics market will grow from $13.02 billion in 2022 to $14.68 billion in 2023 at a compound annual growth rate (CAGR) of 12.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global bioinformatics market is expected to grow to $24.46 billion in 2027 at a CAGR of 13.6%. Increasing demand for protein sequencing is driving growth in the bioinformatics market. Protein sequencing refers to the process of determining the sequence of amino acids in all or part of the proteins present in DNA, based on which specific functions, activities, origin, or localization of the protein are determined. Protein sequencing helps analysts to understand the distribution of amino acids along the sequences and the structure of proteins. With bioinformatics methods and databases, the capacity, structure, and developmental history of proteins can be effectively identified. The demand for protein sequencing is expected to grow on account of factors such as advancements in clinical mass spectrometry and analytical techniques, and the significant adoption of target-based drug development by pharmaceutical and biotechnology companies. For instance, in 2021, the total number of protein sequences in UniProtKB, which is a freely accessible database of protein sequence and functional information, increased to approximately 190 million. The lack of interoperability among various available data formats is acting as a restraint on the bioinformatics market. Various data formats come with differences in structures of data. There are numerous protein databases available through various resources, and each database chooses to represent proteins in a different format. Also, different data models such as object data model or relational data model are used while collecting data. Therefore, the problem of interoperability arises when a researcher tries to integrate the results of unique databases present in different data formats. Various data formats available for bioinformatics include Compressed Row Storage (CRS), Sparse Vector, Avro, Parquet and ORC (Optimized Row Compressed). According to a report by Pharmaphorum, an estimated 80% of the researchers’ time is spent on data grooming and only 20% on actual data analysis. This is essentially due to the lack of standardized file types and inconsistent data formatting, which means that every new program results in a new data format. The interoperability issues arising from the use of multiple data formats are affecting the market growth. Companies in the bioinformatics market are increasingly investing in the research and development of nanopore sequencing technology. Nanopore sequencing is a single molecule DNA sequencing technology that eliminates the need for Polymerase Chain Reaction or chemical labeling of the sample. This technology passes ionic current through nanopores (a pore of nanometer size) and when the biological molecules pass through the nanopores or near to it them this technology measures the changes in current which can be used to identify the molecule. Nanopore sequencing technology offers high throughput, low cost, longer reads (Sequence of a section of a unique fragment) to the analyst and helps in the collection of data which is an essential part of bioinformatics. For instance, in 2020, Oxford Nanopore Technologies raised $109.5 million to support the ramp of commercial and manufacturing operations and to further develop its nanopore technology. The bioinformatics market is governed by various regulatory bodies for quality and compliance of bioinformatics platforms. For instance, in India, the Biotechnology Industry Research Assistance Council (BIRAC), set up by Department of Biotechnology (DBT), Government of India, regulates the bioinformatics market. BIRAC introduces Technology Readiness Levels (TRLs) as a measure of estimating the maturity of technology while in the evaluation phases until these technologies are complete to be offered commercially. The TRL scale provides 9 technology readiness levels with TRL1 being the stage when the technology is ideated, and TRL9 being the stage when the technology is ready for commercial use. The manufacturers have to get past TRL9 to have their products available commercially and ready to be marketed. These TRL's consist of various levels of compliance and processes that the manufacturers must adhere to. The bioinformatics platform is evaluated for quality, feasibility, data privacy, and protection as per international standards. In September 2020, APIS Assay Technologies Ltd., a UK-based Biotechnology company acquired BeoGenomics for an undisclosed amount. With the addition of Beogenomics’ proven expertise in bioinformatics APIS Assay Technologies Ltd can more effectively capture the exciting opportunities presented in the bioinformatics space. BeoGenomics, a USA-based bioinformatics company that focuses on NGS, SNP chip, and GeneChip genomic data processing and analysis. Major players in the bioinformatics market are Agilent Technologies, Illumina, QIAGEN, Affymetrix, Thermo Fisher Scientific, BGI, Dassault Systems, Eurofins scientific, Bruker Daltonics, Biomax Informatix, DNASTAR, Partek, Geneva Bioinformatics, Perkinelmer Inc., Accelrys, SA Nonlinear Dynamics, Quest Diagnostics, Sophia Genetics, Waters Corporation, Permin Elmer Inc., Applied Biologicals Materials., Life Technologies, PerkinElmer, Waters Corporation, Sophia Genetics, Celera, Tripos, LP, Helicos Biosciences Incorporation, and IBM Life Sciences. North America was the largest region in the bioinformatics market in 2022. Western Europe was the second largest region in the global bioinformatics market. The regions covered in the global bioinformatics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the bioinformatics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The bioinformatics market includes revenues earned by entities by providing solutions which combine computer programming, information engineering, mathematics, and statistics to analyze biological data for drug discovery and preclinical studies. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global bioinformatics market is segmented - 1) By Products and Serivces: Knowledge Management Tools, Data Analysis Platforms, Services 2) By Application: Metabolomics, Molecular Phylogenetics, Transcriptomics, Proteomics, Chemoinformatics, Genomics, Other Applications 3) By End Users: Pharmaceutics, Animal Study, Agriculture, Forensic Science, Other End Users

Metabolomics is a branch of bio-analytics that deals with the quantification and identification of metabolic small molecules found in cells, tissues, organs, and biological fluids.Research in the area of metabolomics focuses on the chemical reactions that metabolites go through. The main products and services of metabolomics are metabolomics instruments, metabolomics bioinformatics tools, and services. Metabolomics instruments are devices used to extensively examine low-molecular-weight compounds in biological samples. The various metabolomics instruments include separation techniques, detection techniques, and metabolomics bioinformatics tools and services involving bioinformatics tools and databases, as well as bioinformatics services. The different indications are cancer, cardiovascular disorders, neurological disorders, inborn errors of metabolism, and others that are applied in biomarker discovery, drug discovery, toxicology testing, nutrigenomics, functional genomics, personalized medicine, and others. The metabolomics market research report is one of a series of new reports from The Business Research Company that provides metabolomics market statistics, including metabolomics industry global market size, regional shares, competitors with a metabolomics market share, detailed metabolomics market segments, market trends and opportunities, and any further data you may need to thrive in the metabolomics industry. This metabolomics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global metabolomics market will grow from $2.69 billion in 2022 to $3.09 billion in 2023 at a compound annual growth rate (CAGR) of 14.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global metabolomics market is expected to grow to $5.61 billion in 2027 at a CAGR of 16.1%. The increasing prevalence rate of cancer drives the metabolomics market growth. Metabolomics screens the potential biomarkers (specific cells, molecules, or genes, gene products, enzymes, or hormones) to measure the cancer drug responsiveness aiding early diagnosis. For instance, according to a report by WebMD,an American publisher of health related news, in 2021, 10 million people died of cancer worldwide. In 2020, according to the American Cancer Society, lung cancer is the leading cancer killer in both men and women in the USA, there were 228,820 new cancer cases and 135,720 deaths. Metabolomics approaches such as nuclear magnetic resonance (NMR) technique and mass spectrometry (MS) techniques have been used to study cancer. Companies like Metabolon Inc., Bruker Corp., and others have adopted metabolomics as a tool for early detection and cure for cancer. The increasing complexity in interpreting data act as a restraint hindering the metabolomics market growth. Metabolomics tools generate huge quantum of data through metabolomics techniques and the generated data keeps changing not static, hence increasing the difficultly in interpretation of data. For instance, data generated by nuclear magnetic resonance (NMR) Spectroscopy, an analytical technique used for metabolic profiling (a method to measure and interpret various low molecular weight and other intermediates), is difficult to process and interpret. High-level statistical techniques are required for classification and analysis of this data to uncover the biological knowledge which is time-consuming and expensive, restraining the metabolomics market growth. Machine learning is increasing its popularity in the field of metabolomics due to improving efficiency in the interpretation of data generated from metabolomics techniques. Machine learning-enabled technologies help in the automation of risky and complex processes, avoid repetitive and time taking processes, provide quick and error-free services. Companies in the industry are preferring machine learning techniques for metabolism analysis to solve problems, automate processes and execute tasks. Some of the machine learning algorithms aid in metabolism data analysis and metabolic pathway modelling. Some of the companies such as Bio-Rad Laboratories, Metabolon Inc. and others have started using machine learning algorithms for better understanding and prediction in metabolomics study. For instance, MeltDB 2.0, a machine learning software used as a tool for the analysis and integration of metabolomics experiment data that aids research, store experimental data sets. Such machine learning software offer comprehensive analysis and visualization features for the proper representation of the large complex data. Clinical Microbiomics, a Denmark-based microbiome research company, acquired MS-Omics for an undisclosed amount. The acquisition added specialized metabolic profiling offerings to its portfolio, which will advance its systems biology platform and help researchers all around the world. MS-Omics is a Denmark-based metabolomics company. Major players in the metabolomics market are Human Metabolome Technologies, Metabolon, Bio-Rad Laboratories, Bruker, Agilent Technologies, Thermo Fisher, Waters, Biocrates Life Sciences, Shimadzu, Danaher Corporation, Kore Technologies Ltd., Dani Instruments S.P.A, Perkinelmer Inc., Evans Analytical Group LLC., LECO Corporation, Phenomenome Discoveries Inc., AB Sciex, BG Medicine Inc., Biomark Diagnostics Inc., Chenomx Inc., Creative Proteomics, Evotec A.G, and Merck kgaA. 3d North America was the largest region in the metabolomics market in 2022. Western Europe was the second largest region in the global metabolomics market. The regions covered in the global metabolomics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the metabolomics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The metabolomics market includes revenue earned by liquid chromatography, gas chromatography, capillary electrophoresis, mass spectrometry, and nuclear magnetic resonance spectroscopy. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global metabolomics market is segmented - 1) By Product & Service: Metabolomics Instruments, Metabolomics Bioinformatics Tools & Services 2) By Application: Biomarker Discovery, Drug Discovery, Toxicology Testing, Nutrigenomics, Functional Genomics, Personalized Medicine, Other Applications 3) By Indication: Cancer, Cardiovascular Disorders, Neurological Disorders, Inborn Errors of Metabolism, Other Indications 4) By Metabolomics Instruments: Separation Techniques, Detection Techniques 5) By Metabolomics Bioinformatics Tools & Services: Bioinformatics Tools and Database, Bioinformatics Services

Laboratory automation systems refer to the use of instruments to carry out laboratory tasks with a minimum of human involvement. Clinical laboratories operate more efficiently because of laboratory automation, which helps to standardise tests. The main equipment and software of laboratory automation systems are automated liquid handling, microplate readers, standalone robots, automated storage and retrieval systems, software, informatics, and other equipment. The microplate reader is an instrument that is used to measure biological, chemical or physical reactions of analytes within the wells of the microplate. The various types include modular automation, total lab automation that is used in applications such as drug discovery, clinical diagnostics, genomics solutions, proteomics solutions, and other applications. The end users covered in this market are biotechnology and pharmaceutical industries, research institutes, hospitals, private labs, and academic institutes. The laboratory automation systems market research report is one of a series of new reports from The Business Research Company that provides laboratory automation systems market statistics, including laboratory automation systems industry global market size, regional shares, competitors with a laboratory automation systems market share, detailed laboratory automation systems market segments, market trends and opportunities, and any further data you may need to thrive in the laboratory automation systems industry. This laboratory automation systems market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global laboratory automation systems market grew from $5.87 billion in 2022 to $6.21 billion in 2023 at a compound annual growth rate (CAGR) of 5.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The laboratory automation systems market is expected to grow from $7.43 billion in 2027 at a CAGR of 4.6%. Increased demand for microbiology testing and standardization of sample-collection devices for microbiology culture has driven the adoption of automated laboratory systems for culture-based laboratory testing in clinical microbiology. Culture-based microbiology laboratory testing by manual methods is being replaced by automated methods with the help of total laboratory automation. For instance, popular systems such as Becton Dickinson’s Kiestra TLA, Copan’s WASPLab, and others enable total laboratory automation (TLA) for culture-based microbiology testing. The potential to affect laboratory efficiency, turnaround time, and the overall quality of culture-based microbiology testing, is driving the automated laboratory systems market growth. The laboratory automation systems market growth is limited due to a severe shortage of skilled and trained healthcare professionals for operating the advanced laboratory equipment which requires specialized skillsets. These skillsets are limited to some hospitals, research organizations, and medical equipment companies in the USA and Europe, this is expected to be a major restraint on the market. 40% of the healthcare industry was facing difficulties in hiring process development staff due to a shortage of talent. According to the American Society for Clinical Pathology (ASCP) survey, average job-vacancy rates exceed 50% in some states. This shortage also led to a rise in competition and salaries for the limited talent pool available, thereby further limiting the market growth. The hospital laboratories are increasingly adopting RFID technology for laboratory automation systems due to its better productivity and product quality reduced costs for technology, error reduction, faster delivery of samples, and reduced human intervention. Radio Frequency Identification (RFID) technology is an automatic system of identification based on wireless communication, consisting of a tag and a reader which can communicate through radiofrequency. RFID technology is similar to bar code technology but is more beneficial as it can perform some additional functions and actions automatically without human intervention than bar code technology. An RFID system is equipped with a transponder, transceiver, and a data processing unit to meet enhanced identification and tracking requirements in hospital laboratories. Laboratory automated systems use RFID tags attached with patient samples for identification and smart cards to store patients’ data under a workstation that monitors the process in the laboratory. For instance, Mayo Clinic, a healthcare company, adopted RFID-enabled laboratory automation systems to minimize errors by 70%, maximize efficiency and patient safety, and reduce specimen turnaround time by 50%. Food and Drug Administration (FDA) Center for Devices and Radiological Health (CDRH) is responsible for technologies, devices, medical or surgical equipment, support systems, and laboratory instruments, systems, and equipment. FDA sent a device recall notice to enGen Laboratory Automation System, a medical device manufacturer, for its product-enGen Track System with TCAutomation Software Version 4.2. This recall acts as a product correction notification as a laboratory system with TCA Software V4.2 may potentially cause a delay in reporting of results, aid mechanical problems, and inaccurate patient data. To reduce incidences associated with these devices and let the manufacturer communicate and inform about the instructions on how to monitor and correct the issue if it has occurred to the potentially affected enGen customers, the device recall has been made. In March 2021, SPT Labtech, a UK-based automated instrumentation manufacturer, acquired BioMicroLab for an undisclosed amount. The acquisition would strategically expand product offerings of SPT Labtech in the fields of life sciences sample mangament. BioMicroLab is a US-based robotics automation provider for life sciences laboratories. Major players in the laboratory automation systems market are Tecan Group, Perkinelmer, Thermo Fisher Scientific, Agilent Technologies, Danaher, Qiagen, Roche, Abbott, Siemens, and Eppendorf. North America was the largest region in the laboratory automation systems market in 2022. Western Europe was the second largest region in the global laboratory automation systems market. The regions covered in the global laboratory automation systems market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the laboratory automation systems market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The laboratory automation systems market consists of sales of clinical laboratory machines, equipment, and instruments. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global laboratory automation systems market is segmented - 1) By Equipment & Software: Automated Liquid Handling, Microplate Readers, Standalone Robots, Automated Storage And Retrieval Systems, Software And Informatics, Other Equipment 2) By Application: Drug Discovery, Clinical Diagnostics, Genomics Solutions, Proteomics Solutions, Other Applications 3) By End User: Biotechnology And Pharmaceutical Industries, Research Institutes, Hospitals And Private Labs, Academic Institutes 4) By Type: Modular Automation, Total Lab Automation

Molecular diagnostics devices are used to diagnose infectious diseases and perform screening by detecting specific sequences in DNA or RNA. It helps doctors prescribe more accurate therapeutic interventions in the early stages of a disease.  The main products of molecular diagnostics devices (or) equipment are instruments, reagents, and consumables. A reagent is a substance that is used to cause a chemical reaction. Reagents are used to indicate the presence of another substance. The technologies involved are DNA (deoxyribonucleic acid) sequencing, polymerase chain reaction, isothermal nucleic acid amplification technology, transcription-mediated amplification (TMA), in situ hybridization, microarrays, mass spectrometry, and others (southern blotting, northern blotting, and electrophoresis). The various applications are cancer, pharmacogenomics, genetic testing, infectious disease, prenatal, neurological disease, and cardiovascular disease, which are used by various end-users such as diagnostic laboratories, hospitals, and others (nursing homes, blood banks, point of care). The molecular diagnostics devices (or) equipment market research report is one of a series of new reports from The Business Research Company that provides molecular diagnostics devices (or) equipment market statistics, including molecular diagnostics devices (or) equipment industry global market size, regional shares, competitors with a molecular diagnostics devices (or) equipment market share, detailed molecular diagnostics devices (or) equipment market segments, market trends and opportunities, and any further data you may need to thrive in the molecular diagnostics devices (or) equipment industry. This molecular diagnostics devices (or) equipment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global molecular diagnostics devices and equipment market size will grow from $27.65 billion in 2022 to $30.82 billion in 2023 at a compound annual growth rate (CAGR) of 11.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The molecular diagnostics devices and equipment market size is expected to grow from $43.28 billion in 2027 at a CAGR of 8.9%. The growth in the molecular diagnostic devices and equipment market is attributed to factors such as the rapid rise in various bacterial and viral epidemics. The increase in the spread of diseases increases the demand for early and improved diagnostic methods. To improve the technology to enable the early diagnosis of such diseases, the Government and different organizations extend their financial support towards the major key players of the industry. For example, according to the reports from Centres for Disease Control and Prevention (CDC) US in October 2021, melioidosis was declared as a multistate epidemic. Thus, the rise of such chronic diseases serves as a prime driver for the players in the industry to develop more accurate and sophisticated diagnostic devices and equipment. Following the increase in demand for early diagnosis of B. pseudomallei, InBios, launched Active Meliodosis Detect™ point of care diagnostic test for the detection of B. pseudomallei. The regulatory process involving the approval of molecular diagnostic tests is often slow. The lack of clear definition coupled with constant changes in the regulations is a challenge for companies developing these kits. In developing nations such as India and China lack of a well-defined regulatory framework negatively impacts the market, irrespective of the presence of a large population. In the US market, because of the changes in the rules and regulations, the products already in the market may also be required to go through Food and Drug Administration (FDA)’s pre-marketing approval process. For example, CLIA (Clinical Laboratory Improvement Amendments Act) in the US certifies the validity of laboratory-based tests but it does not regulate the clinical validity of molecular diagnostic tests. This means that it does not control whether these results are clinically correct. This argument puts a restraint on the industry and opens an argument that FDA should play a greater role in overseeing laboratories. The major players in the molecular diagnostic industry are focusing on developing automated solutions for devices and equipment used for molecular diagnostic processes. Automation of the process will help to enhance the productivity and consistency of the whole diagnostic process. Computerization of the diagnostic process gives reliable and efficient test results that manual testing by various experts does not. The major players of the industry are using nanotechnology-based Oral Fluid Nano Sensor Test (OFNASET). The test uses a microfluidic-based nanosensor for the detection of oral cancer biomarkers in saliva. To keep up with the trend of automation and accuracy, Roche, created cobas connection modules (CCM) to improve scalability and sample-flow efficiency by allowing samples to automatically move between different systems and instruments. Thus, creating a fully automated workflow. The molecular diagnostic devices in the US are approved by Food and Drug Administration's (FDA) Center for Devices and Radiological Health (CDRH). These diagnostics devices are generally approved with an accompanying assay, to evaluate their safety and effectiveness or substantial equivalence regarding the assays they run and the assay's defined performance parameters. However, the same instruments do not require FDA approval or clearance when used for basic scientific research purposes. The European regulatory landscape has become more stringent and technically challenging for medical device companies. The introduction of four different risk classes of diagnostic devices i.e. classes A-D. Class A refers to the lowest risk tests and class D refers to the highest risk test such as HIV testing, blood grouping, and prenatal testing. Most of the genetic testing is classed into class C. The products bearing a CE mark, European approved tests, are safe to use, and are in full compliance. In March 2021, BioFire Diagnostics receive first marketing authorization from U.S. FDA for its BioFire Respiratory Panel 2.1. The product is a diagnostic product for simultaneous detection of multiple respiratory viral and bacterial nucleic acids in nasopharyngeal swabs obtained from patients. Major players in the molecular diagnostics devices (or) equipment market are Roche Ltd., Hologic, QIAGEN, Abbott, Danaher Corporation, Bio-Rad Laboratories, Siemens Healthcare, Becton Dickinson and Company, Cepheid Inc., and bioMerieux S.A. Asia-Pacific was the largest region in the global molecular diagnostics devices (or) equipment market in 2022. Western Europe was the second largest market in molecular diagnostics devices (or) equipment market. The regions covered in the global molecular diagnostics devices (or) equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the molecular diagnostics devices (or) equipment market are Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, UK, USA, and Australia. The molecular diagnostics devices and equipment market consits of sales of thermocycler, single particle mass spectrometers, time-of-flight mass spectrometer (TOF) and others that are used to to detect pathogen and infectious diseases. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. This market is segmented into instruments, reagents, and consumables. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global molecular diagnostics devices and equipment market is segmented - 1) By Product: Instruments, Reagents, Consumables 2) By End User: Diagnostic laboratories, Hospitals, Others( nursing home, blood banks, point of care) 3) By Technology: DNA(Deoxyribonucleic acid) sequencing, Polymerase chain reaction, Isothermal Nucleic Acid Amplification Technology, Transcription Mediated Amplification (TMA), In situ hybridization, Microarrays, Mass spectrometry, Others (southern blotting, northern blotting, electrophoresis) 4) By Application: Cancer, Pharmacogenomics, Genetic testing, Infectious disease, Prenatal, Neurological disease, Cardiovascular disease

Microbiome refers to a group of microbes that live in a certain habitat and include fungi, bacteria, and viruses. It is all of the bacteria, fungi, protozoa, and viruses' genetic material that dwells on and within the human body. The microbiome's bacteria also aid in digestion, immune system control, defence against disease-causing bacteria, and the production of vitamins like Vitamin K, which is required for blood clotting, and the B vitamins B12, thiamine, and riboflavin. The main types of microbiomes are faecal microbiota transplantation (FMT) and microbiome drugs. The technique of transferring faecal bacteria and other germs from one healthy person to another is known as faecal microbiota transplantation or stool transplantation. The different technologies include genomics, proteomics, and metabolomics and are used in inflammatory bowel disease, diabetes, multiple sclerosis, rheumatoid arthritis, and others. The microbiome market research report is one of a series of new reports from The Business Research Company that provides microbiome market statistics, including microbiome industry global market size, regional shares, competitors with a microbiome market share, detailed microbiome market segments, market trends, and opportunities, and any further data you may need to thrive in the microbiome industry. This microbiome market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global microbiome market size will grow from $0.39 billion in 2022 to $0.57 billion in 2023 at a compound annual growth rate (CAGR) of 45.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global microbiome market size is expected to grow from $1.09 billion in 2027 at a CAGR of 17.6%. The increasing prevalence of inflammatory bowel disease (IBD) is a key factor driving the growth of the microbiome market. Inflammatory bowel disease (IBD) is a multifactorial and autoimmune infection group consisting of two major entities such as ulcerative colitis (UC) and Crohn's disease (CD). Fecal microbiota transplantation (FMT) and probiotics were discovered as having potential applications in many immune-mediated disorders, such as IBD, to restore microbial balance. These microbial therapies have shown the potential to reduce both the dysbiotic condition and the development of inflammatory mediators, thereby enabling remission, particularly in UC. For instance, in September 2020, according to the National Institute of Health, a US-based biomedical and public health research agency, between 600,000 and 900,000 Americans may suffer from ulcerative colitis. Therefore, the increasing prevalence of inflammatory bowel disease (IBD) is expected to drive the growth of the microbiome market. The high cost of microbial therapy is a key factor hampering the growth of the microbiome market. The price of fecal transplantation, a microbial therapy, may vary considerably depending on the delivery method used by users and where users receive it. Fecal microbiota transplant processes can charge around $600-$1,000 based on the method of treatment, area, insurance coverage, and other variables. Therefore, the high cost of microbial therapy is expected to hinder the growth of the microbiome market. The growing technological improvement is a major trend gaining popularity in the microbiome market. Major companies in the microbiome sector are focusing on developing advanced technology solutions for microbiomes. For instance, Seed, a new microbiome company, has introduced Probiotic and Prebiotic Daily Synbiotic for both females and males. The Daily Synbiotic Seed is the first to follow a microbe-system strategy with strain-specific advantages beyond digestive health such as cardiac safety, dermatological health, immune control, reproductive health, the integrity of the gut barrier, and oxidative stress. In January 2021, Novozymes, a Denmark-based biotechnology company, acquired Microbiome Labs for an undisclosed amount. Microbiome Labs’ acquisition is a crucial step in expanding Novozymes’ Human Health platform, giving it exposure to a wide range of patented solutions as well as access to the firm’s network of health professionals. Microbiome Labs is a probiotics company based in the United States. Major players in the microbiome market are MicroBiome Therapeutics LLC., Seres Therapeutics, Enterome Bioscience, Second Genome, Vedanta Biosciences Inc., AbbVie Inc., Rebiotix, Inc., Ritter Pharmaceuticals, LNC Therapeutics Inc., and ViThera Pharmaceuticals Inc. North America was the largest region in the microbiome market in 2022. The regions covered in the global microbiome market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the microbiome market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The microbiome market consists of sales of firmicutes, bacteroidetes, and actinobacteria. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain or as part of other products. The global microbiome market is segmented - 1) By Type: Fecal Microbiota Transplantation (FMT), Microbiome Drugs 2) By Application: Inflammatory Bowel Disease, Diabetes, Multiple Sclerosis, Rheumatoid Arthritis, Other Applications 3) By Technology: Genomics, Proteomics, and Metabolomics

Research antibodies and reagents refer to the antibodies that bioscientists utilise as basic detection techniques. These are used to designate and distinguish particular proteins that are found within the sick cell at a particular stage of its life cycle. The main types of technologies in research antibodies and reagents are western blot, immunofluorescence, immunohistochemistry, flow cytometry, enzyme-linked immunosorbent assay (ELISA), multiplex immunosorbent assay, immunoprecipitation, and others. The western blot, also known as western blotting, is molecular biology and immunogenetics analytical technique for detecting specific proteins in a sample of tissue homogenate or extract. The different applications include proteomics, drug discovery & development, and genomics and are implemented in various sectors such as the pharmaceutical & biotechnology industry, academic & research institutes, and contract research organizations (CROs). The research antibodies and reagents market research report is one of a series of new reports from The Business Research Company that provides research antibodies and reagents market statistics, including research antibodies and reagents industry global market size, regional shares, competitors with a research antibodies and reagents market share, detailed research antibodies and reagents market segments, market trends and opportunities, and any further data you may need to thrive in the research antibodies and reagents industry. This research antibodies and reagents market research report deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global research antibodies and reagents market grew from $13.19 billion in 2022 to $14.02 billion in 2023 at a compound annual growth rate (CAGR) of 6.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The research antibodies and reagents market is expected to grow from $18.85 billion in 2027 at a CAGR of 7.7%. Increasing investment in medical and health research and development (R&D) is predicted to contribute to the growth of the research antibodies and reagents market. In the field of life science research, antibodies and reagents are essential components for the investigation of biological processes or causes of diseases through careful experimentation, observation, laboratory work, analysis, and testing. For instance, in April 2021, according to a report published by the Congressional Budget Office, a US-based government agency that provides budget and economic information, pharmaceutical companies will have invested $83 billion on research and development activities around the world. According to the Assobiotec publication BioInItaly 2020, healthcare is involved in 49% of the over 700 biotech firms headquartered in Italy. Thus, increasing investment in healthcare research and development will increase the utilization of the research antibody and reagent market. Reproducibility issues of antibodies and reagents are expected to hamper the growth of the research antibodies and reagents market. Reproducibility is the ability of an experiment or calculation to be duplicated by other researchers working independently. The prevalence of irreproducible preclinical research exceeded 50%, resulting in approximately $28 billion spent on preclinical research every year. Among the irreproducible research, the largest fraction of about 36% is assigned to biological reagents, which amounts to $10 billion annually. This huge research waste is due to insufficiently validated antibodies and irreproducible reagents that are not appropriate for the target proteins. Thus, reproducibility issues with antibodies and reagents are expected to restrain market growth. Technological advancements in the area of purification of antibodies and reagents show opportunities for the growth of the research antibodies and reagents market during the forecast period. Irreproducible antibodies and reagents are a major challenge for the industry, as this will affect the outcome of the research. For instance, in July 2020, Sysmex Corporation, a Japan based diagnostic tools manufacturing company, launched antibody measurement technology for the Coronavirus (SARS-CoV-2) Antibody Lab Assay Service and Antibody Measurement Reagents. These tools were employed in a clinical performance assessment that involved IgG antibody detection. They were utilized to compare IgG antibody concentrations in relation to circulating N and S antigens between SARS-CoV-2 patients and a group of SARS-CoV-2 patients after leaving the hospital. In February 2022, Rockland Immunochemicals, Inc., a US-based company that specializes in the development of assays and basic research tools using antibodies, acquired Antibodies-Online GmbH for an undisclosed amount. Through this acquisition, Rockland, utilizing the reputable e-commerce brand, extensive supplier network, and proprietary technology stack of antibodies-online, achieves excellence in the design, development, and manufacture of antibodies and assays. Customers of each business will have access to improved capabilities supported by richer and more comprehensive data sets, enhancing their overall customer experience and boosting their go-to-market strategy. Antibodies-Online GmbH is a Germany based company that provides antibodies, reagents, and research kits to companies. Major players in the research antibodies and reagents market are Becton Dickinson and Company, Thermo Fisher Scientific Inc., Bio-Rad Laboratories Inc., F. Hoffmann-La Roche Ltd., Merck KGaA, PerkinElmer Inc., Lonza Group AG, Abcam PLC., GenScript Biotech Corporation, and Bio-Techne Corporation. North America was the largest region in the research antibodies and reagents market in 2022. The regions covered in the global research antibodies and reagents market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the research antibodies and reagents market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The research antibodies and reagents market consists of sales of buffers, fixatives, solvents, and enzymes. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The global research antibodies and reagents market is segmented - 1) By Technology: Western Blot, Immunofluorescence, Immunohistochemistry, Flow Cytometry, Enzyme-linked Immunosorbent Assay (ELISA), Multiplex Immunosorbent Assay, Immunoprecipitation, Other Technologies 2) By Application: Proteomics, Drug Discovery & Development, Genomics 3) By End-User: Pharmaceutical & Biotechnology Industry, Academic & Research Institutes, Contract Research Organizations (CROs)

The molecular diagnostics market consists of sales of molecular diagnostics services and related products by entities (organizations, sole traders, partnership) that are utilised to direct patient management, from diagnosis to treatment, especially in the treatment of congenital anomalies, infectious diseases, and cancer. Molecular diagnostic is a term used to describe a class of techniques that are used to examine biological markers in the genetic code (genome) of an organism and to determine how its cells express their genes as proteins. The main types of products in molecular diagnostics are instruments, reagents, consumables, software, and services. Instruments refer to a measuring device for determining the present value of a quantity under observation. The technologies include polymerase chain reaction (PCR), DNA sequencing, and next-generation sequencing, and these are used in oncology, pharmacogenomics, infectious diseases, genetic testing, neurological disease, cardiovascular disease, microbiology, and other applications. The various end-users are hospitals, laboratories, and other end-users (blood banks, home health agencies, and nursing homes). The global molecular diagnostics market size is expected to grow from $49.49 billion in 2021 to $49.64 billion in 2022 at a compound annual growth rate (CAGR) of 0.3%. The global molecular diagnostics market size is expected to decline to $47.78 billion in 2026 at a compound annual growth rate (CAGR) of -1.0%. The rising prevalence of infectious diseases and cancers of different forms drives the molecular diagnostics market. To determine whether mutations to a gene or chromosome may raise a person's chance of acquiring cancer or other disorders, molecular testing is employed. The increasing prevalence of infectious diseases and various types of cancer creates a demand for new diagnostic procedures, including fast and specific molecular diagnostic tests. For instance, in 2020, according to the National Cancer Institute, a US-based government agency, an estimated 1,806,590 new cases of cancer would be diagnosed in the United States and 606,520 people would die from the disease. Therefore, the increasing prevalence of cancer is driving the growth of the molecular diagnostic market. The advances in genomics and proteomics are a key trend gaining popularity in the molecular diagnostics market. Polymerase chain reaction (PCR) is a recent development in genomics and helps in discovering new approaches to molecular diagnosis for disease diagnosis and pathogenesis of diseases. This enables better monitoring and a fast diagnosis and major organizations are investing to have a competitive edge. Following the trend, $600 million to support the COVID-19 vaccine and therapy clinical trials led by the private sector and for Canadian bio-manufacturing opportunities. This announcement was part of the $1 billion Plan to Mobilize Science. The growing research in proteomics and genomics will help develop more advanced molecular diagnostic techniques in the forecast period. In April 2021, Hologic, a US-based women’s health technology company, acquired Mobidiag Oy for an undisclosed amount. The acquisition would accelerate the global growth of Mobidiag’s molecular diagnostic test platforms, which offer ease of use, multiplex capability, and rapid turnaround time. Mobidiag Oy is a Finland-based company that develops and provides molecular diagnostics for infectious diseases and antibiotic resistance. The major players in the molecular diagnostics market are Becton, BioMérieux SA, Danaher Corporation, Grifols, Hologic Inc., Novartis AG, QIAGEN, Siemens Healthcare GmbH, Abbott, and Dickinson and Company. North America was the largest region in the molecular diagnostics market in 2021. The regions covered in the global molecular diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the molecular diagnostics market are Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, the UK, the USA, and Australia. The global molecular diagnostics market is segmented - 1) By Technology: Polymerase Chain Reaction (PCR), DNA Sequencing, and Next-Generation Sequencing 2) By Product: Instruments, Reagents and Consumables, Software and Services 3) By Application: Oncology, Pharmacogenomics, Infectious Diseases, Genetic Testing, Neurological Disease, Cardiovascular Disease, Microbiology, and Others 4) By End-User: Hospitals, Laboratories, and Others (Blood Banks, Home Health Agencies, and Nursing Homes)